by Arkansas Business Staff
on Tuesday, Jun. 13, 2017 4:54 pm
1 min read
Akeso Biomedical of Fayetteville on Tuesday announced that it has closed its most recent round of financing with $4.4 million from existing and new investors.
Akeso will use some of the funds to develop manufacturing and global distribution partnerships for TYPLEX Chelate, the first product that uses its Fe3C technology.
TYPLEX Chelate is a feed additive that inhibits colonization of animal hosts by bacterial pathogens, thereby reducing the risk of foodborne illness and improving animal performance and value on the farm, the company said. The non-antibiotic product inhibits pathogenic bacteria, such as Clostridium, Campylobacter, Salmonella and E. coli from adhering to avian gut walls, allowing better nutrient absorption and growth.
Akeso said the new funding will also allow it to pursue other applications of its technology in animal health, including commercialization of feed additives for piglets, as well as poultry.
The top stories of the day, right to your inbox
click here to read more.